| Schedule of Segment Reporting Information |
Cash,
cash equivalents and marketable securities were as follows at June 30, 2026 and December 31, 2025:
Schedule
of Segment Reporting Information
| | |
June
30, 2026 | | |
December
31, 2025 | |
| Cash | |
$ | 1,384,101 | | |
$ | 2,883,305 | |
| Cash equivalents | |
| 5,276,069 | | |
| 1,539,533 | |
| Marketable securities | |
| 701,085 | | |
| 5,696,386 | |
Research
and development study and material costs were as follows during the three and six months ended June 30, 2026 and 2025:
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
Three Months
Ended | | |
Six Months
Ended | |
| | |
June
30, | | |
June
30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Research and development studies | |
$ | 883,252 | | |
$ | 1,884,150 | | |
$ | 1,653,211 | | |
$ | 3,947,886 | |
| Research and development
materials | |
| 44,714 | | |
| 62,046 | | |
| 79,158 | | |
| 124,561 | |
| Research and development
costs | |
$ | 927,966 | | |
$ | 1,946,196 | | |
$ | 1,732,369 | | |
$ | 4,072,447 | |
|